Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Infectious Diseases

    Naval Medical Center San Diego Administers Hospital’s First mAb Treatment to COVID-19 Patient

    By Global Biodefense StaffJanuary 30, 2021
    Lt. Cmdr. Raben Talvo, Naval Medical Center San Diego's (NMCSD) Office of Clinical Quality department head, administers the hospital’s first monoclonal antibody (mAb) treatment, bamlanivimab, to a COVID-19-positive patient Jan. 26. Credit: Harley Sarmiento
    Share
    Facebook LinkedIn Reddit Email

    Naval Medical Center San Diego (NMCSD) administered the hospital’s first monoclonal antibody (mAb) treatment to a COVID-19-positive patient Jan. 26. The intravenous infusion is

    Bamlanivimab is approved for emergency use authorization (EUA) guidance from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients 12 years or older with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19.

    “The treatment is infused via IV, and [is designed] to decrease or slow down the replication of the virus in the patient,” said Lt. Cmdr. Raben Talvo, NMCSD’s Office of Clinical Quality department head. “We’re preventing the patient’s symptoms from getting worse, thus lessening the strain on our healthcare facility.”

    Talvo, a registered nurse, administered the mAb treatment and adhered to the FDA’s high-risk patient guidelines.

    “[The treatment] is a one time, one hour infusion plus one hour of observation,” said Talvo. “It’s key for us to identify potential patients who have not only tested positive for COVID-19, but have experienced an onset of symptoms within 10 days before we can offer this treatment. These potential patients would have had mild to moderate symptoms for 10 days or less, and this treatment is not for people who are currently admitted into a hospital due to their symptoms.”

    Lt. Cmdr. Alison Lane, NMCSD’s Infectious Diseases division head, said the hospital offers the mAb treatment infusion to all eligible patients, but the decision to proceed is reached via an individualized, shared decision-making process with each patient.
    “Getting the mAb treatment to the right patients at the right time to safely maximize potential benefits is logistically challenging,” said Lane.

    Capt. Juliann Althoff, NMCSD’s chief medical officer with a background in preventative medicine and a public health physician by trade, said the mAb therapy is currently being administered through local health systems and other military training facilities.
    “It’s given as an outpatient infusion with the goal of minimizing severe illness and hospitalizations,” said Althoff. “In addition to the public health essentials of physical distancing and mask-wearing, and the upcoming rollouts of vaccines, [mAb therapy] is an additional option we can now offer our beneficiaries.”

    Lane echoed her colleagues’ thoughts that preventing hospital admissions for COVID-19 is not only beneficial to individual patients, but also reduces strain on this hospital and the healthcare system as a whole.

    Article adapted from original story by Jacob L. Greenberg, Naval Medical Center San Diego

    COVID Countermeasures COVID-19 Editor Pick Medicine-Health SARS-CoV-2 Therapeutic Antibodies
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleCOVID-19 Misinformation on Chinese Social Media – Lessons for Countering Conspiracy Theories
    Next Article Should People Who Have Recently Had COVID-19 Be Vaccinated?

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.